B. Laffranchi

496 total citations
18 papers, 409 citations indexed

About

B. Laffranchi is a scholar working on Oncology, Hematology and Cell Biology. According to data from OpenAlex, B. Laffranchi has authored 18 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Hematology and 5 papers in Cell Biology. Recurrent topics in B. Laffranchi's work include Microtubule and mitosis dynamics (5 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). B. Laffranchi is often cited by papers focused on Microtubule and mitosis dynamics (5 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). B. Laffranchi collaborates with scholars based in Italy, United States and Germany. B. Laffranchi's co-authors include Mariangela Mariani, Silvia Comis, Maurizio Rocchetti, Neeltje Steeghs, Hans Gelderblom, Maja J.A. de Jonge, R. Spinelli, Ferry A.L.M. Eskens, J.W.R. Nortier and Jan Ouwerkerk and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

B. Laffranchi

18 papers receiving 403 citations

Peers

B. Laffranchi
Mei-Li Wen United States
Karl Hsu United States
Malathi Kandarpa United States
Lauren Moran United States
Mitchell J. Geer United States
Timothy N. Trotter United States
Luigia Rao Italy
Tao Osgood United States
Sujata Chakraborty United States
Lurdes Torres Portugal
Mei-Li Wen United States
B. Laffranchi
Citations per year, relative to B. Laffranchi B. Laffranchi (= 1×) peers Mei-Li Wen

Countries citing papers authored by B. Laffranchi

Since Specialization
Citations

This map shows the geographic impact of B. Laffranchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Laffranchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Laffranchi more than expected).

Fields of papers citing papers by B. Laffranchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Laffranchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Laffranchi. The network helps show where B. Laffranchi may publish in the future.

Co-authorship network of co-authors of B. Laffranchi

This figure shows the co-authorship network connecting the top 25 collaborators of B. Laffranchi. A scholar is included among the top collaborators of B. Laffranchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Laffranchi. B. Laffranchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Macarulla, Teresa, Andrés Cervantes, Josep Tabernero, et al.. (2015). Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. British Journal of Cancer. 112(12). 1874–1881. 30 indexed citations
2.
Verslype, Chris, Pascal Hammel, Manuel Hidalgo, et al.. (2013). Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.. Journal of Clinical Oncology. 31(15_suppl). 4041–4041. 5 indexed citations
3.
Macarulla, Teresa, Josep Tabernero, Andrés Cervantes, et al.. (2012). PD-0024 Phase I/II Study of Folfiri Plus the MEK1/2 Inhibitor Pimasertib (MSC1936369B) as Second-Line Treatment for KRAS Mutated Metastatic Colorectal Cancer. Annals of Oncology. 23. iv27–iv27. 12 indexed citations
4.
Massard, Christophe, Jean‐Charles Soria, Alan Anthoney, et al.. (2011). A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 10(6). 963–970. 44 indexed citations
5.
Steeghs, Neeltje, Ron H.J. Mathijssen, Judith A.M. Wessels, et al.. (2010). Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Investigational New Drugs. 29(5). 953–962. 15 indexed citations
6.
Laffranchi, B., Maja J. De Jonge, E. Bajetta, et al.. (2010). Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).. Journal of Clinical Oncology. 28(15_suppl). e13558–e13558. 6 indexed citations
7.
Bahleda, Ratislav, Anna Spreafico, Jean‐Charles Soria, et al.. (2010). Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3063–3063. 2 indexed citations
8.
Cohen, Roger B., Suzanne F. Jones, Charu Aggarwal, et al.. (2009). A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(21). 6694–6701. 78 indexed citations
9.
10.
Izzo, Francesco, Annamaria Catino, Thomas J. Vogl, et al.. (2009). Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results. Journal of Clinical Oncology. 27(15_suppl). 4593–4593. 1 indexed citations
11.
Steeghs, Neeltje, Ferry A.L.M. Eskens, Hans Gelderblom, et al.. (2009). Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology. 27(30). 5094–5101. 91 indexed citations
12.
Cohen, Richard B., Suzanne F. Jones, Margaret von Mehren, et al.. (2008). Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2520–2520. 11 indexed citations
13.
Jonge, Maja J.A. de, Neeltje Steeghs, Jaco J. Verweij, et al.. (2008). Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3507–3507. 6 indexed citations
14.
Lim, Soon Thye, Luis Fayad, Anil Tulpule, et al.. (2007). A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leukemia & lymphoma. 48(2). 374–380. 23 indexed citations
15.
Paquette, Ronald, Neil P. Shah, Charles L. Sawyers, et al.. (2007). PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.. Blood. 110(11). 1030–1030. 44 indexed citations
16.
Burris, H.A., G. R. Hudes, Joyce Cheng, et al.. (2006). 343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor. European Journal of Cancer Supplements. 4(12). 107–107. 4 indexed citations
17.
18.
Herbrecht, Raoul, Peter Borchmann, Martin Wilhelm, et al.. (2004). Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.. Blood. 104(11). 2489–2489. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mei-Li Wen Breakdown of academic impact, for papers by Karl Hsu Breakdown of academic impact, for papers by Malathi Kandarpa Breakdown of academic impact, for papers by Lauren Moran Breakdown of academic impact, for papers by Mitchell J. Geer Breakdown of academic impact, for papers by Timothy N. Trotter Breakdown of academic impact, for papers by Luigia Rao Breakdown of academic impact, for papers by Tao Osgood Breakdown of academic impact, for papers by Sujata Chakraborty Breakdown of academic impact, for papers by Lurdes Torres
Rankless by CCL
2026